Supernus Pharmaceuticals announced that Trokendi XR (topiramate extended-release) capsules for the treatment of epilepsy are now available.
Trokendi XR is a once-daily antiepileptic drug (AED) indicated for:
- Initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures
- Adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures
- Adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome
The precise mechanism by which topiramate exerts its anticonvulsant effects are unknown. However, evidence suggests that, at pharmacologically relevant concentrations, topiramate blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainite subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.
The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
For more information call (301) 838-2500 or visit Supernus.com.